Taewan Kim

Prof. Dr. Taewan Kim

Shenzhen University International Cancer Center
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2016 in Nature Communications
Verified
Journal Article
Open access
CLChia-Wei Li
Chia-Wei Li
SLSeung-Oe Lim
Seung-Oe Lim
WXWeiya Xia
Weiya Xia
HLHeng-Huan Lee
Heng-Huan Lee
LCLi-Chuan Chan
Li-Chuan Chan
MHMien-Chie Hung
Mien-Chie Hung
Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation. We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degradation of PD-L1 by β-TrCP. In-depth analysis of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP. We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer. Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models. Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.

1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
SLSeung-Oe Lim
Seung-Oe Lim
CLChia-Wei Li
Chia-Wei Li
WXWeiya Xia
Weiya Xia
JCJong-Ho Cha
Jong-Ho Cha
LCLi-Chuan Chan
Li-Chuan Chan
MHMien-Chie Hung
Mien-Chie Hung

1 August 2018 in Molecular Cell
Verified
Journal Article
Closed access
JCJong-Ho Cha
Jong-Ho Cha
WYWen-Hao Yang
Wen-Hao Yang
WXWeiya Xia
Weiya Xia
YWYongkun Wei
Yongkun Wei
LCLi-Chuan Chan
Li-Chuan Chan
MHMien-Chie Hung
Mien-Chie Hung

1 February 2018 in Cancer Cell
Verified
Journal Article
Closed access
CLChia-Wei Li
Chia-Wei Li
SLSeung-Oe Lim
Seung-Oe Lim
ECEzra M. Chung
Ezra M. Chung
YKYong-Soo Kim
Yong-Soo Kim
APAndrew H. Park
Andrew H. Park
MHMien-Chie Hung
Mien-Chie Hung

25 April 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
TKTaewan Kim
Taewan Kim
Angelo VeroneseAngelo Veronese
Angelo Veronese
FPFlavia Pichiorri
Flavia Pichiorri
TLTae Jin Lee
Tae Jin Lee
YJYoung-Jun Jeon
Young-Jun Jeon
CCCarlo Crocecarlo
Carlo Crocecarlo
P53 suppresses tumor progression and metastasis. Epithelial–mesenchymal transition (EMT) is a key process in tumor progression and metastasis. The transcription factors ZEB1 and ZEB2 promote EMT. Here, we show that p53 suppresses EMT by repressing expression of ZEB1 and ZEB2. By profiling 92 primary hepatocellular carcinomas (HCCs) and 9 HCC cell lines, we found that p53 up-regulates microRNAs (miRNAs), including miR-200 and miR-192 family members. The miR-200 family members transactivated by p53 then repress ZEB1/2 expression. p53-regulated miR-192 family members also repress ZEB2 expression. Inhibition or overexpression of the miRNAs affects p53-regulated EMT by altering ZEB1 and ZEB2 expression. Our findings indicate that p53 can regulate EMT, and that p53-regulated miRNAs are critical mediators of p53-regulated EMT.

10 July 2023 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
TKTaewan Kim
Taewan Kim
CCCarlo Crocecarlo
Carlo Crocecarlo
As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.